Nymox Pharmaceutical Corporation (NYMXF)

Nymox Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	-	-	-	0.01	0.12
Revenue Growth (YoY)	-	-	-	-95.69%	-61.20%
Cost of Revenue	-	-	-	0	0.06
Gross Profit	-	-	-	0	0.06
Selling, General & Admin	4.36	2.88	5.85	3.6	6.01
Research & Development	3.99	3.77	6.66	8.12	7.38
Operating Expenses	8.35	6.65	12.5	11.72	13.38
Operating Income	-8.35	-6.65	-12.5	-11.72	-13.33
Interest Expense	-0.06	-0.04	-0.04	-0.04	-0.04
Interest & Investment Income	0.01	0	0.01	0.03	0.21
Currency Exchange Gain (Loss)	0	0.01	-0	-0	-0.01
Other Non Operating Income (Expenses)	-	0.11	-	-	-
EBT Excluding Unusual Items	-8.4	-6.58	-12.54	-11.74	-13.16
Other Unusual Items	-0.44	-	-	-	-
Pretax Income	-8.84	-6.58	-12.54	-11.74	-13.16
Net Income	-8.84	-6.58	-12.54	-11.74	-13.16
Net Income to Common	-8.84	-6.58	-12.54	-11.74	-13.16
Shares Outstanding (Basic)	92	89	82	74	69
Shares Outstanding (Diluted)	92	89	82	74	69
Shares Change (YoY)	2.58%	9.04%	11.04%	7.23%	13.86%
EPS (Basic)	-0.10	-0.07	-0.15	-0.16	-0.19
EPS (Diluted)	-0.10	-0.07	-0.15	-0.16	-0.19
Free Cash Flow	-4.06	-5.21	-9.83	-10.05	-7.43
Free Cash Flow Per Share	-0.04	-0.06	-0.12	-0.14	-0.11
Gross Margin	-	-	-	20.00%	50.00%
Operating Margin	-	-	-	-234400.00%	-11487.07%
Profit Margin	-	-	-	-234760.00%	-11346.55%
Free Cash Flow Margin	-	-	-	-201000.00%	-6405.17%
EBITDA	-8.34	-6.64	-12.49	-11.71	-13.32
D&A For EBITDA	0.01	0.01	0.01	0.01	0.01
EBIT	-8.35	-6.65	-12.5	-11.72	-13.33
Revenue as Reported	-	-	-	0.01	0.12

Updated Jan 2, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.